RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Key Highlights
- ➤Q3 2026 results scheduled for November 5 after market close
- ➤Q2 2026 RenovoCath revenue reached record $909,000
- ➤TIGeR-PaC Phase III trial fully enrolled in August 2026
- ➤TIGeR-PaC completion expected first half 2027; topline data second half 2027
- ➤2025 RenovoCath sales totaled approximately $1.1 million
MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath(®), a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026. RenovoRx will host a conference call and webcast at 4:30 p.m. ET following the release.
During the call, management will discuss the Company’s commercial execution, the drivers of its commercial success, and the foundation it believes is in place for continued revenue growth and cash generation.
Get started
Create a free account to read the full story.